Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: A systematic literature review

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 8, 2013, Pages 931-951

  Hendriks, A G M ^a   Keijsers, R R M C ^a   De Jong, E M G J ^a   Seyger, M M B ^a   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DIFLORASONE; DIFLORASONE DIACETATE; FLUOCINOLONE; FLUOCINONIDE; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; RETINOID; TACALCITOL; TAZAROTENE; VITAMIN D;

BURNING SENSATION; COCHRANE LIBRARY; CREAM; DRUG EFFICACY; DRUG SAFETY; EMBASE; ERYTHEMA; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MEDLINE; MONOTHERAPY; OINTMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALP; SKIN IRRITATION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CALCINEURIN; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; RETINOIDS; VITAMIN D;

EID: 84880507330     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12058     Document Type: Review

References (88)

1. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
2. Albrecht L, Bourcier M, Ashkenas J,. Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. J Cutan Med Surg 2011; 15: 309-321.
3. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; 15: CD005028.
4. Hendriks AG, Keijsers RR, de Jong EM, et al. Combinations of classical time-honored topicals in plaque psoriasis: A systematic review. J Eur Acad Dermatol Venereol 2012. 10.1111/j.1468-3083.2012.04640.x. [Epub ahead of print].
5. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM,. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62: 1013-1030.
6. Oxford Centre for Evidence-based Medicine Levels of Evidence. Home page (March 2009) URL http://www.cebm.net/index.aspx?o=1025 (last accessed 2 May 2011).
7. Lopez N, Cabra B, Castillo R, et al. Unilateral blaschkolinear psoriasis. Eur J Dermatol 2008; 18: 457-458.
8. Feldman SR,. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis 2007; 80: 20-28.
9. Koo JY,. Relevance of the COBRA trial in current psoriasis practice. Cutis 2007; 80: 4-11.
10. Mrowietz U, Zaumseil RP,. Sequential combination therapy with Psorcutan Beta and Psorcutan of patients with psoriasis: An observational study in 1500 patients [German]. Aktuelle Dermatologie 2005; 31: 448-454.
11. Kira M, Katayama I,. Superimposed linear psoriasis. J Dermatol 2010; 37: 1063-1065.
12. Griffiths MR, Porter W, Fergusson-Wood LA, Adriaans B,. Generalized pustular psoriasis complicated by acute respiratory distress syndrome. Br J Dermatol 2006; 155: 496-497.
13. Vakirlis E, Kastanis A, Lazaridou E, et al. Treatment of guttate psoriasis with a new twocompound product containing calcipotriol and betamethasone dipropionate. Int J Clin Pharmacol Res 2005; 25: 165-168.
14. Katoulis AC, Bozi E, Kanelleas A, et al. Psoriasiform fixed drug eruption caused by nimesulide. Clin Exp Dermatol 2009; 34: e360-e361.
15. Peter C Jr, Rosenman K, Cheung W, et al. Linear psoriasis. Dermatol Online J 2009; 15: 4.
16. Sotiriadis D, Patsatsi A, Sotiriou E, et al. Acrodermatitis continua of Hallopeau on toes successfully treated with a two-compound product containing calcipotriol and betamethasone dipropionate. J Dermatolog Treat 2007; 18: 315-318.
17. Vena GA, Cassano N, Agnusdei CP, et al. Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur J Inflammation 2005; 3: 37-41.
18. Augustin M, Peeters P, Radtke M, et al. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007; 215: 219-228.
19. Fleming C, Ganslandt C, Leese GP,. Short- and long-term safety assessment of a twocompound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol 2010; 9: 969-974.
20. Hagen AD, Sulit DJ, Sulit AK,. Cutaneous psoriasis in a military flight surgeon. Aviat Space Environ Med 2006; 77: 140-144.
21. Hino R, Kabashima R, Kawakami C, et al. Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate. J Eur Acad Dermatol Venereol 2011; 25: 242-244.
22. Rosina P, Giovannini A, Gisondi P, Girolomoni G,. Microcirculatory modifications of psoriatic lesions during topical therapy. Skin Res Technol 2009; 15: 135-138.
23. Wozel G,. Effectiveness of combined treatment of calcipotriol and fluocinololone acetonide in psoriasis plaque test. Aktuelle Dermatologie 1994; 20: 155-158. Available at: http://www.mrw.interscience.wiley.com/cochrane/ clcentral/articles/651/CN-00358651/frame.html (last accessed 7 August 2012).
24. Wu JK, Siller G, Strutton G,. Psoriasis induced by topical imiquimod. Australas J Dermatol 2004; 45: 47-50.
25. Mrowietz U, Macheleidt O, Eicke C,. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol((R)) -gel): results. J Dtsch Dermatol Ges 2011; 9: 825-831.
26. Lebwohl M, Colon LE,. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. Cutis 2007; 80: 29-40.
27. Clareus BW, Houwing R, Sindrup JH, Wigchert S,. The DESIRE study-Psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. Eur J Dermatol 2009; 19: 581-585.
28. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-1394.
29. Coimbra S, Oliveira H, Reis F, et al. Health-related quality of life in Portuguese psoriatic patients: Relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment. J Dermatol 2011; 38: 816-819.
30. Augustin M, Radtke M, van Engen A, et al. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2009; 7: 329-338.
31. Bovenschen JH, Erceg A, Van Vlijmen-Willems I, et al. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: Effects on T-cell infiltration, epidermal proliferation and keratinization. J Dermatol Treat 2007; 18: 32-39.
32. Glade CP, van Erp PE, Boezeman JB, van de Kerkhof PC,. Multiparameter flow cytometry as a tool to evaluate antipsoriatic therapy. Br J Dermatol 1997; 137: 367-375.
33. Peeters P, Ortonne JP, Sitbon R, Guignard E,. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. Dermatology 2005; 211: 139-145.
34. Glade CP, Van Erp PE, Van De Kerkhof PC,. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study. Br J Dermatol 1996; 135: 379-384.
35. Queille-Roussel C, Hoffmann V, Enevold A, Ganslandt C,. Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis. J Dermatolog Treat 2011; [Epub ahead of print].
36. Duweb G, Alhaddar J, Elsherif B, et al. Calcipotriol-betamethasone ointment versus calcipotriol ointment in the treatment of psoriasis vulgaris. Drugs Exp Clin Res 2005; 31: 175-179.
37. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-471.
38. Koo J, Blum RR, Lebwohl M,. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 2006; 55: 637-641.
39. Lebwohl M, Yoles A, Lombardi K, Lou W,. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39: 447-450.
40. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.
41. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, doubleblind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-326.
42. Katoh N, Kishimoto S,. Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis. Eur J Dermatol 2003; 13: 382-384.
43. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268-269.
44. Lahfa M, Mrowietz U, Koenig M, Simon JC,. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol 2003; 13: 261-265.
45. Ruzicka T, Lorenz B,. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-258.
46. Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 2007; 18: 361-365.
47. Cassano N, Miracapillo A, Coviello C, et al. Treatment of psoriasis vulgaris with the twocompound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig 2006; 26: 227-233.
48. Erceg A, Bovenschen HJ, van de Kerkhof PC, Seyger MM,. Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. Br J Dermatol 2006; 155: 110-114.
49. Ortonne JP, Kaufmann R, Lecha M, Goodfield M,. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209: 308-313.
50. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393.
51. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-135.
52. Guenther L, Cambazard F, Van De Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, doubleblind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
53. Menter A, Abramovits W, Colon LE, et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009; 8: 52-57.
54. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54.
55. White S, Vender R, Thaçi D, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol 2006; 7: 177-184. Available at: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/ 631/CN-00570631/frame.html (last accessed 7 August 2012).
56. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-654.
57. Ortonne JP, Noerrelund KL, Papp K, et al. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. Eur J Dermatol 2010; 20: 585-589.
58. Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology 2011; 222: 148-156.
59. van der Velden HM, Pasch MC, van Erp PE, et al. Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study. J Dermatolog Treat 2010; 21: 13-22.
60. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-1173.
61. Salmhofer W, Maier H, Soyer HP, et al. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl (Stockh) 2000; 211: 5-8.
62. Calzavara-Pinton P, Rossi MT, Sala R, Venturini M,. The separate daily application of tacalcitol 4 microg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 microg/g and betamethasone dipropionate 0.5 mg/g. G Ital Dermatol Venereol 2011; 146: 295-299.
63. Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate twocompound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino andBlack/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol 2010; 49: 1328-1333.
64. Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161: 159-166.
65. Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107-113.
66. Van De Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-176.
67. Jemec GBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-463.
68. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217: 321-328.
69. Cassano N, Vena GA,. Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product. Acta Derm Venereol 2007; 87: 85-86.
70. Downs AM,. Dovobet ointment under occlusion overnight for troublesome scalp psoriasis. Acta Derm Venereol 2006; 86: 57-58.
71. Hudson CP, Kempers S, Menter A, et al. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis 2011; 88: 201-207.
72. Patel T, Bhutani T, Busse KL, Koo J,. Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial. Cutis 2011; 88: 149-154.
73. European Medicines Agency. Clinical Investigation of Corticosteroids Intended for Use on the Skin ". 1987. Available at: URL http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003328.pdf (last accessed 7 August 2012).
74. Bowman PH, Maloney JE, Koo JY,. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002; 46: 907-913.
75. Dhawan SS, Blyumin ML, Pearce DJ, Feldman SR,. Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis. J Drugs Dermatol 2005; 4: 228-230.
76. Green L, Sadoff W,. A clinical evaluation of tazarotene 0.1% gel, with and without a highor mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002; 6: 95-102.
77. Lebwohl M, Lombardi K, Tan MH,. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001; 40: 64-66.
78. Tanghetti EA,. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis 2000; 66: 4-11.
79. Coynik D,. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. Cutis 2000; 66: 19-24.
80. Guenther LC, Poulin YP, Pariser DM,. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22: 1225-1238.
81. Poulin YP,. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 1999; 63: 41-48.
82. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39: 590-596.
83. McMichael AJ, Griffiths CEM, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996; 135: 60-64.
84. Stücker M, Hoffmann M, Altmeyer P, Instrumental evaluation of retinoid-induced skin irritation. Skin research and technology: official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 2002. Available at: http://www.mrw. interscience.wiley.com/cochrane/clcentral/articles/871/CN-00408871/frame.html (last accessed 7 August 2012).
85. Koo JY, Martin D,. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001; 40: 210-212.
86. Buder K, Knuschke P, Wozel G,. Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHzultrasonography and optical coherence tomography. Int J Clin Pharmacol Ther 2010; 48: 814-820.
87. Brill TJ, Elshorst-Schmidt T, Valesky EM, et al. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology 2005; 211: 351-355.
88. Kaidbey K, Kopper SC, Sefton J, Gibson JR,. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol 2001; 40: 468-471.